AbbVie Inc. $ABBV Shares Sold by CX Institutional

CX Institutional reduced its position in AbbVie Inc. (NYSE:ABBV) by 13.0% during the 2nd quarter, HoldingsChannel reports. The institutional investor owned 78,286 shares of the company’s stock after selling 11,667 shares during the period. CX Institutional’s holdings in AbbVie were worth $19,700,000 at the end of the most recent quarter.

A number of other hedge funds and other institutional investors have also recently added to or reduced their stakes in ABBV. Bank of Jackson Hole Trust increased its stake in AbbVie by 0.6% during the fourth quarter. Bank of Jackson Hole Trust now owns 7,213 shares of the company’s stock worth $1,648,000 after acquiring an additional 44 shares during the last quarter. Eclectic Associates Inc. ADV lifted its stake in shares of AbbVie by 0.8% in the 4th quarter. Eclectic Associates Inc. ADV now owns 5,852 shares of the company’s stock valued at $1,337,000 after purchasing an additional 45 shares in the last quarter. Imprint Wealth LLC lifted its stake in shares of AbbVie by 56.2% in the 4th quarter. Imprint Wealth LLC now owns 125 shares of the company’s stock valued at $29,000 after purchasing an additional 45 shares in the last quarter. Dogwood Wealth Management LLC grew its holdings in shares of AbbVie by 10.8% during the 4th quarter. Dogwood Wealth Management LLC now owns 473 shares of the company’s stock worth $108,000 after purchasing an additional 46 shares during the period. Finally, Quantum Private Wealth LLC grew its holdings in shares of AbbVie by 2.0% during the 4th quarter. Quantum Private Wealth LLC now owns 2,376 shares of the company’s stock worth $543,000 after purchasing an additional 46 shares during the period. Institutional investors and hedge funds own 70.23% of the company’s stock.

AbbVie Stock Performance

AbbVie stock opened at $244.62 on Tuesday. The firm has a market capitalization of $432.19 billion, a PE ratio of 69.10, a price-to-earnings-growth ratio of 0.83 and a beta of 0.30. AbbVie Inc. has a one year low of $190.75 and a one year high of $267.47. The stock’s 50 day moving average price is $239.67 and its 200 day moving average price is $224.25.

AbbVie (NYSE:ABBV) last issued its quarterly earnings data on Friday, July 31st. The company reported $3.65 earnings per share (EPS) for the quarter, beating the consensus estimate of $3.61 by $0.04. The company had revenue of $16.99 billion during the quarter, compared to the consensus estimate of $16.80 billion. AbbVie had a net margin of 9.80% and a negative return on equity of 466.39%. AbbVie’s revenue for the quarter was up 10.2% on a year-over-year basis. During the same quarter last year, the company earned $2.97 earnings per share. AbbVie has set its Q3 2026 guidance at 3.840-3.880 EPS. On average, analysts forecast that AbbVie Inc. will post 14.12 earnings per share for the current fiscal year.

AbbVie Dividend Announcement

The company also recently declared a quarterly dividend, which will be paid on Friday, August 14th. Investors of record on Wednesday, July 15th will be issued a dividend of $1.73 per share. This represents a $6.92 dividend on an annualized basis and a yield of 2.8%. The ex-dividend date of this dividend is Wednesday, July 15th. AbbVie’s dividend payout ratio (DPR) is presently 195.48%.

Wall Street Analyst Weigh In

ABBV has been the topic of several research reports. Wall Street Zen lowered shares of AbbVie from a “strong-buy” rating to a “buy” rating in a report on Sunday, July 5th. HSBC reiterated a “buy” rating and set a $300.00 price objective on shares of AbbVie in a research note on Monday, July 6th. Weiss Ratings reissued a “hold (c)” rating on shares of AbbVie in a research report on Monday, June 8th. Barclays raised their target price on shares of AbbVie from $275.00 to $300.00 and gave the company an “overweight” rating in a research note on Wednesday, July 29th. Finally, Citigroup upped their price target on shares of AbbVie from $230.00 to $260.00 and gave the stock a “neutral” rating in a research report on Wednesday, July 15th. Two analysts have rated the stock with a Strong Buy rating, seventeen have assigned a Buy rating and six have assigned a Hold rating to the company’s stock. According to MarketBeat.com, AbbVie presently has an average rating of “Moderate Buy” and a consensus price target of $271.48.

More AbbVie News

Here are the key news stories impacting AbbVie this week:

• Positive Sentiment: AbbVie reported strong second-quarter results, with revenue up 10.2% year over year and adjusted earnings per share exceeding consensus estimates. Growth from Skyrizi, Rinvoq and neuroscience products helped offset the continuing decline of Humira. AbbVie: Strong Q2 And New Catalysts Keep Me Bullish
• Positive Sentiment: Cantor Fitzgerald raised its AbbVie price target from $265 to $285 and maintained an “overweight” rating, reflecting confidence in the company’s growth outlook and pipeline.
• Positive Sentiment: New oncology opportunities could provide additional long-term growth. AbbVie’s telisotuzumab adizutecan is cited as an emerging targeted treatment in esophageal cancer, while the late-stage ABBV-706 trial is testing another potential therapy in small-cell lung cancer. Esophageal Cancer Market Outlook
• Neutral Sentiment: Analyst commentary remains broadly constructive, with some estimates suggesting shares could approach $300, supported by AbbVie’s dividend profile and the performance of newer growth products. AbbVie Quietly Solved Its Biggest Problem—Now What?
• Negative Sentiment: The Apogee Therapeutics acquisition is reducing projected 2026 earnings per share while increasing research and development costs. Although AbbVie raised its revenue outlook, the earnings dilution and weaker near-term guidance have prompted investor caution. ABBV Q2 Earnings Call Balances Growth With Apogee Dilution

AbbVie Profile

AbbVie is a global, research-driven biopharmaceutical company that was created as a spin-off from Abbott Laboratories in 2013 and is headquartered in North Chicago, Illinois. The company focuses on discovering, developing and commercializing therapies for complex and often chronic medical conditions. Its operations span research and development, manufacturing, regulatory affairs and commercialization, with an emphasis on bringing specialty medicines to market across multiple therapeutic areas.

AbbVie’s product portfolio and pipeline cover several major therapeutic categories, including immunology, oncology, neuroscience, virology and women’s health.